Business
Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting
WALTHAM, Mass., April 14, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., April 14, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced three presentations at the upcoming 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting being held April 27 - 28, 2020.\nSpecial Session Details\nTitle: A first-in-class Menin-MLL1 antagonist for the treatment of MLL-r and NPM1 mutant leukemiasPresenter: Gerard McGeehan, Ph.D.Session: New Drugs on the HorizonSession Date and Time: Mon., April 27, 2020; 4:54 p.m. – 5:14 p.m. ET\nThe New Drugs on the Horizon session will feature discussions of innovative small molecules and biologics that have recently entered Phase I clinical trials. The session will include a presentation on SNDX-5613, the Company's oral Menin inhibitor, including a brief update of the ongoing AUGMENT-101 trial.\nOral Presentation Details\nTitle: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 monotherapy in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumorsFirst author: Nilo Azad, M.D.Session: Phase I Clinical TrialsAbstract Number: CT149 Session Date and Time: Mon., April 27, 2020; 9:00 a.m. - 6:00 p.m. ET\nTitle: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in combination with durvalumab in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumorsFirst author: Anthony W. Tolcher, M.D.Session: Phase I Trials in ProgressAbstract Number: CT242Session Date and Time: Mon., April 27, 2020; 9:00 a.m. - 6:00 p.m. ET\nSession information is available online via the Annual Meeting Itinerary Planner through the AACR website at www.aacr.org.\nAbout Syndax Pharmaceuticals, Inc. \nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, is being tested in a Phase 3 combination trial with exemestane for treatment of advanced HR+, HER2- breast cancer and has been evaluated in combinat...